Jacobio Pharma
IPOPublic · Beijing, China · $55.0M raised
- Headquarters
- Beijing
- Employees
- 51–200
- Business Model
- B2B
- Website
- jacobiopharma.com
- Total Funding
- $55.0M
- Last Round
- $55.0M Series CAug 2018
- Rounds
- 2
- Type
- Public
About
China-based oncology drug discovery company developing induced allosteric inhibitors targeting the KRAS pathway and STING pathway.
Summary
Jacobio Pharma is an Oncology company based in Beijing, China. It has raised $55.0M in total across 2 rounds, most recently a $55.0M Series C round in Aug 2018. Investors include Qiming VP, Hillhouse Capital and Lilly Asia Ventures.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2020
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Artificial intelligence for drug discovery.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...